Inbiomotion Launches MAF Test in US via NeoGenomics to Guide Adjuvant Bisphosphonate Use in Early Breast Cancer

The MAF Test, a tissue-based diagnostic from Barcelona’s Inbiomotion that identifies which early breast cancer patients benefit from adjuvant bisphosphonates, became available across the United States on November 18 through NeoGenomics Laboratories — challenging menopausal status as the standard filter for these bone-protecting drugs, Oncodaily reported.

For more than a decade, the question hanging over adjuvant bisphosphonates in early breast cancer has been blunt: which patients actually benefit? Current guidelines answer with menopause. ESMO recommends them for postmenopausal women at intermediate to high risk of recurrence.

That approach reflects trial data in which recurrence and survival benefits appeared confined to postmenopausal women — for reasons that have remained unclear. Inbiomotion argues tumor biology, not menopausal status, should drive the decision.

“U.S. availability marks a major step in making precision medicine a reality,” said Joël Jean-Mairet, PhD, Executive Chairperson of Inbiomotion. He said the company aims to improve outcomes and reduce unnecessary treatment.

Lab Test May Guide Bone Drug Use

  • A simple lab test on your original breast tumor may soon help your oncologist decide whether bone-strengthening drugs belong in your treatment plan — regardless of whether you have gone through menopause.
  • About 80% of patients in the trial specimens were MAF-negative, meaning most tested patients fell into the group that appeared to benefit.

How the MAF Gene Rewrites the Bisphosphonate Question

The test is a FISH-based assay — fluorescence in situ hybridization, a technique that uses fluorescent probes to detect specific genetic changes — run on tissue from the primary breast tumor. It detects amplification of the MAF gene at chromosome locus 16q23. When amplified, tumors overproduce MAF, a transcription factor tied to metastasis, particularly to bone.

The implication cuts both ways.

What AZURE and NSABP B-34 Actually Showed

The evidence base comes from retrospective biomarker analyses — studies run on archived tumor samples after the trials ended — of two large adjuvant trials. Both were designed to test the drugs, not the biomarker, and in both the MAF testing was done blind at a central laboratory.

AZURE tested zoledronic acid and enrolled 3,360 patients with stage II–III disease; results were published in The Lancet Oncology in 2017.

The finding that stood out came from MAF-positive patients who were not postmenopausal.

Of 2,533 available tumor samples, 1,883 were evaluable. In MAF-amplified tumors, clodronate showed no benefit, with possible harm in some subgroups.

Trial Drug Patients randomized Evaluable MAF samples MAF-negative benefit
AZURE (2017) Zoledronic acid 3,360 865 of 1,739 HR 0.74 (iDFS)
NSABP B-34 (2021) Oral clodronate 3,323 1,883 of 2,533 HR 0.70 (DFS), HR 0.59 (OS)

Company Funded Biomarker Analyses

Transparency matters here. Inbiomotion helped fund both biomarker analyses, and company founders and executives — including Roger Gomis and Jean-Mairet — are co-authors.

Not everyone is convinced. In October 2025, Health Technology Wales concluded the evidence was insufficient to support routine adoption of MAF testing. It noted the data come from retrospective subgroup analyses of trials that did not test MAF-guided treatment prospectively.

Guideline traction has been uneven. It grades that statement III, B — a weaker evidence grade — compared with I, A for its core bisphosphonate recommendation.

The Regulatory Gap in US Practice

One point matters for American patients.

Oncologists and pathologists can order the test through NeoGenomics, the Fort Myers, Florida-based provider of oncology diagnostics that runs a network of CAP-accredited, CLIA-certified laboratories across the country.

Contraindications & When to Consult a Doctor

The announcement did not include specimen requirements, turnaround time, price or the test’s US regulatory status, so patients should confirm coverage and logistics with their care team and insurer.

Three Questions Shape US Adoption

The US is the largest market yet for a test Inbiomotion launched in May 2023.

Three questions will shape what happens next: whether US payers reimburse the test; whether US panels such as NCCN and ASCO take a position on MAF testing; and whether MAF results begin to change who receives adjuvant bisphosphonates in US clinics.

For now, the evidence remains retrospective, the guideline grade remains modest, and Health Technology Wales has asked for prospective studies. Whether US practice adopts a biomarker over menopause is the question no one has yet answered.

References

  • AZURE trial biomarker analysis, The Lancet Oncology, 2017
  • NSABP B-34 MAF analysis, JNCI Cancer Spectrum, 2021
  • ASCO–Ontario Health (Cancer Care Ontario) adjuvant bisphosphonate guideline
  • SEOM-GEICAM-SOLTI clinical guidelines for early-stage breast cancer, 2025 update
  • Health Technology Wales appraisal of MAF testing, October 2025

Discuss treatment decisions with a qualified oncologist.

Photo of author

Health Desk

Health Desk at Archyde.

Lakers Host Jazz on Nov 18 as 9-Game Streak Faces Back-to-Back Test